Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
来源：PubMed发布日期：2026-07-09作者：Melero I, de Miguel M, Cabanas EG, de Velasco G, Joerger M0 次点击